14,653 reports of this reaction
10.3% of all INFLIXIMAB DYYB reports
#1 most reported adverse reaction
OFF LABEL USE is the #1 most commonly reported adverse reaction for INFLIXIMAB DYYB, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 14,653 FDA adverse event reports linking INFLIXIMAB DYYB to OFF LABEL USE. This represents approximately 10.3% of all 142,758 adverse event reports for this drug.
Patients taking INFLIXIMAB DYYB who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is a frequently reported adverse event for INFLIXIMAB DYYB, accounting for a significant proportion of all reports.
In addition to off label use, the following adverse reactions have been reported for INFLIXIMAB DYYB:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 14,653 FDA reports for INFLIXIMAB DYYB. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 10.3% of all adverse event reports for INFLIXIMAB DYYB, making it one of the most commonly reported side effect.
If you experience off label use while taking INFLIXIMAB DYYB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.